In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles

Jaehong Key, Christy Cooper, Ah Young Kim, Deepika Dhawan, Deborah W. Knapp, Kwangmeyung Kim, Jae Hyung Park, Kuiwon Choi, Ick Chan Kwon, Kinam Park, James F. Leary

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


One difficulty of diagnosing and treating cancer is that it is very challenging to detect cancers in the early stages before metastasis occurs. A variety of imaging modalities needs to be used from non-invasive, moderate resolution modalities, such as magnetic resonance imaging (MRI) to very high-resolution (e.g. fluorescence) imaging that can help guide surgeons during a surgical operation. While MRI can have relatively high resolution and deep penetration to visualize soft tissues, low sensitivity of MRI frequently requires tumor imaging agents to enhance the MRI contrast at the tumor site. At the other end of the resolution spectrum, near infrared fluorescence (NIRF) imaging has very high sensitivity but frequently cannot be utilized for initial human in vivo imaging due to its very limited penetration depth. To combine the advantages of each imaging modality we have constructed MRI and NIRF dual-modality nanoparticles using glycol chitosan, Cy5.5, and superparamagnetic iron oxide nanoparticles (SPIOs). We have demonstrated these advantages for dual-modality, in vivo tumor imaging in mice. Our studies suggest the potential use of NIRF and MR dual modality imaging for human cancer diagnosis.

Original languageEnglish
Pages (from-to)249-255
Number of pages7
JournalJournal of Controlled Release
Issue number2
StatePublished - 28 Oct 2012

Bibliographical note

Funding Information:
This work was supported by KIST-Purdue GRL (Global Research Laboratory) Collaboration , “Molecular Imaging and Nanomedicine for Theragnosis using NanoBioMaterials”; Grant number: 202979 and the Christopher Columbus Foundation support to JFL. We would like to especially thank Patty I. Bonney, Lindsey M. Fourez, Jane C. Stewart, and Carol Ann Dowell at Purdue University for their assistance with this work. We also express our appreciation to Dr. Aaron Taylor of the Bindley Bioscience Imaging Facility, Dr. Tom Talavage and Greg Tamer of the Purdue MRI facility at Purdue Research Park, and to Debby Sherman and Chia-Ping Huang of the Life Sciences Microscopy Facility at Purdue University for the TEM images, and to Lisa Reece of the Bionano Facility in the Birck Nanotechnology Center supported in part by the Indiana Clinical and Translational Sciences Institute from the National Institutes of Health, National Center for Research Resources, Clinical and Translational Sciences Award.


  • Cancer
  • Chitosan nanoparticle
  • Dual-modality imaging
  • MRI
  • NIRF imaging


Dive into the research topics of 'In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles'. Together they form a unique fingerprint.

Cite this